EUVIMEDEUVIMED entdecken
Open Access

Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin

Stephanie L Egge iD, Samie A Rizvi, Shelby R Simar, Manuel Alcalde, Jose R W Martinez, Blake M Hanson iD, An Q Dinh, Rodrigo P Baptista, Truc T Tran iD, Samuel A Shelburne iD, Jose M Munita, Cesar A Arias iD und 2 weitere

Antimicrobial Agents and Chemotherapy · 07.08.2024 · 68 (8)

DOI: 10.1128/aac.00127-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.08.2024. Verfasst von Stephanie L Egge und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Microbial Sensitivity Tests, Anti-Bacterial Agents, Mutation. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR) P. aeruginosa (PA). FDC circumvents traditional porin and efflux-mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space. Emerging FDC resistance has been associated with loss of function mutations within TBDR genes or the regulatory genes controlling TBDR expression. Further, difficulties with antimicrobial susceptibility testing (AST) and unexpected negative clinical treatment outcomes have prompted concerns for heteroresistance, where a single lineage isolate contains resistant subpopulations not detectable by standard AST. This study aimed to evaluate the prevalence of TBDR mutations among clinical isolates of P. aeruginosa and the phenotypic effect on FDC susceptibility and heteroresistance. We evaluated the sequence of pirR , pirS , pirA , piuA , or piuD from 498 unique isolates collected before the introduction of FDC from four clinical sites in Portland, OR (1), Houston, TX (2), and Santiago, Chile (1). At some clinical sites, TBDR mutations were seen in up to 25% of isolates, and insertion, deletion, or frameshift mutations were predicted to impair protein function were seen in 3% of all isolates ( n = 15). Using population analysis profile testing, we found that P. aeruginosa with major TBDR mutations were enriched for a heteroresistant phenotype and undergo a shift in the susceptibility distribution of the population as compared to susceptible strains with wild-type TBDR genes. Our results indicate that mutations in TBDR genes predate the clinical introduction of FDC, and these mutations may predispose to the emergence of FDC resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaMicrobial Sensitivity TestsAnti-Bacterial AgentsMutationBacterial ProteinsCefiderocolHumansCephalosporinsMembrane ProteinsPseudomonas InfectionsDrug Resistance, Bacterial

Stichwörter der Autor:innen

Gram-negative resistancePseudomonas aeurginosaTonB-dependent receptorbeta-lactamasescefiderocolheteroresistancemulti-drug resistance

Substanzen

Anti-Bacterial AgentsBacterial ProteinsCefiderocolCephalosporinsMembrane ProteinstonB protein, Bacteria

Autor:innen und Institutionen

  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
  • Department of Medicine, Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
  • UTHealth Houston School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.
  • Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clinica Alemana, Universidad del Desarrollo and Multidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), San…
  • Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Macarena, CSIC, Universidad de Sevilla, Seville, Spain.

ORCID-Profile: Stephanie L Egge, Blake M Hanson, Truc T Tran, Samuel A Shelburne, Cesar A Arias, William R Miller

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Egge, S. L., Rizvi, S. A., Simar, S. R., Alcalde, M., Martinez, J. R. W., Hanson, B. M., Dinh, A. Q., Baptista, R. P., Tran, T. T., Shelburne, S. A., Munita, J. M., Arias, C. A., Hakki, M., & Miller, W. R. (2024). Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin. Antimicrobial Agents and Chemotherapy, 68(8). https://doi.org/10.1128/aac.00127-24

Vancouver

Egge SL, Rizvi SA, Simar SR, Alcalde M, Martinez JRW, Hanson BM, et al. Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin. Antimicrobial Agents and Chemotherapy. 2024;68(8). doi:10.1128/aac.00127-24

BibTeX
@article{Egge2024,
  author = {Egge, Stephanie L and Rizvi, Samie A and Simar, Shelby R and Alcalde, Manuel and Martinez, Jose R W and Hanson, Blake M and Dinh, An Q and Baptista, Rodrigo P and Tran, Truc T and Shelburne, Samuel A and Munita, Jose M and Arias, Cesar A and Hakki, Morgan and Miller, William R},
  title = {Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {8},
  doi = {10.1128/aac.00127-24}
}
Kostenlos starten →